Adoptive cell therapy using transferred tumour infiltrating lymphocytes (TILs) is limited by the physical barrier created by a restrictive tumour microenvironment (TME) and by T-cell inactivation within the TME. Thus, minimizing the immunosuppressive effects of the TME and overcoming T-cell inactivation is crucial. AVID200 is a potent TGF-beta inhibitor designed by Forbius that selectively neutralizes […]

AVID200 is a TGF-? trap that specifically sequesters TGF-?I and TGF-?III to enhance antitumour immunity to inhibit tumor growth. AVID200 also avoids adverse side effect of depleted of TGF-?II. AVID200 is relatively short-lived in circulation, decreasing its capacity to exert desirable enhancement of anti-tumour immunity. To increase the effectiveness of TGF-? traps, a panel of […]

AVID100 is an antibody-drug conjugate (ADC) against a validated cancer target that is undergoing IND-enabling studies. Phase I clinical trials are scheduled for late 2016. The monoclonal antibody (mAb) portion of the ADC is currently manufactured using a recombinant CHO clone that fails to meet industrial production yield standards. In order to support clinical phases […]